The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Biotech company Cryosite (CTE) has appointed John Hogg as its new company CEO
  • John has been with the company since July 2018 and was promoted to General Manager of Operations in December 2019
  • He will begin his new role on Monday (October 19)
  • Bryan Dulhunty will step down from his current role as Executive Chairman to non-Executive Chairman
  • On market close, Cryosite is down 5.88 per cent and is trading for 24 cents per share

Biotech company Cryosite (CTE) has appointed John Hogg as CEO as its new company CEO.

John has been with the company since July 2018 and was promoted to General Manager of Operations on December 1, 2019.

He is highly experienced in warehousing, logistics and supply chain management. Previously, John was an independent consultant, contractor and a functional manager for Allergan, Boots International Healthcare, Johnson & Johnson, Philips Electronics, and UTI Worldwide international freight forwarders.

“He has deployed his skills and experience in Australia, Asia and the U.S. John has qualifications in materials management, freight management, accounting and computing, including European Senior Logistician certification and he is a Chartered Member of The Chartered Institute of Logistics and Transport,” the company told the market.

John will begin his new role on Monday (October 19). Bryan Dulhunty will step down from his current role of Executive Chairman to non-executive Chairman.

Bryan was appointed Chairman in March 2018 and then took on the role as Executive Chairman in June 2019. His role was to drive change in the company, the first stage of this change has now been complete.

The future operational development and growth of Cryosite will now be driven by John.

On market close, Cryosite is down 5.88 per cent and is trading for 24 cents per share.

CTE by the numbers
More From The Market Online
advanced mri or ct scan medical diagnosis machine at hospital lab

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Imricor Medical Systems Ltd intends to use the capital raising's funds to support a three-pronged growth…
Abstract visualization of a brain hemorrhage from an MRI perspective, with vivid colors marking the hemorrhagic areas against the brain's grayscale anatomy.

Trial for Alterity’s neurodegenerative drug ATH434 shows reduced disability

An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results…
The Market Online Video

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Recce Pharmaceuticals Ltd has been funded to the tune of US$2M by the US Department of…
AI gen cancer cell

Immutep reports strong response rate from immunotherapies treating carcinomas

Immutep Ltd has reported a slew of positive results from a trial to assess a combination…